Pharmacokinetic mismatch of tuberculosis drugs

Comment

Charles A Peloquin. Antimicrob Agents Chemother. 2012 Mar.

. 2012 Mar;56(3):1666; author reply 1667.

doi: 10.1128/AAC.06303-11.

No abstract available

Comment on

Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
Srivastava S, Sherman C, Meek C, Leff R, Gumbo T. Srivastava S, et al. Antimicrob Agents Chemother. 2011 Nov;55(11):5085-9. doi: 10.1128/AAC.00269-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896907 Free PMC article.

1. Diacon AH, et al. 2007. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51:2994–2996 - PMC - PubMed
1. Dickinson JM, Mitchison DA. 1981. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am. Rev. Respir. Dis. 123:367–371 - PubMed
1. Boulanger C, et al. 2009. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin. Infect. Dis. 49:1305–1311 - PubMed
1. Burman W, et al. 2006. Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med. 173:350–356 - PubMed
1. Jindani A, Doré CJ, Mitchison DA. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167:1348–1354 - PubMed